Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 Mar 2020 07:49

RNS Number : 5885G
4d Pharma PLC
18 March 2020
 

 

 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

Name

Shares in 4D pharma plc before purchase

% of total shares in issue

Shares in 4D pharma plc after purchase

% of total shares in issue

David Norwood (Chairman)

8,457,061

7.7%

 8,557,061

7.8%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Norwood

2

Reason for the notification

a)

Position/status

Chairman/ PDMR

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

4D Pharma plc

b)

LEI

213800O49VYSXWE2ZD52

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

28p

100,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

Date of the transaction

17th March 2020

f)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information please contact:

4D

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXDPFLKEEEA
Date   Source Headline
2nd Aug 20217:00 amRNSTwo MRx0518 presentations accepted for ESMO 2021
29th Jul 20217:00 amRNS$30 Million Credit Facility with Oxford Finance
26th Jul 20211:00 pmRNSPassing of Chief Financial Officer John Beck
6th Jul 20217:00 amRNSPublication - LBP improves activity of CAR-T
29th Jun 20217:00 amRNSLadenburg Thalmann Healthcare Conference
22nd Jun 20217:00 amRNSConference presentation on LBP Manufacturing’
4th Jun 20217:00 amRNSAsthma trial Part A enrolment and program update
1st Jun 20218:52 amRNSTotal Voting Rights
24th May 202110:48 amRNSResult of AGM
24th May 20217:00 amRNSUpdate on Data for Phase II Study of Blautix
17th May 20217:00 amRNSPresentation of Blautix IBS Phase II at DDW 2021
19th Apr 20217:00 amRNSCollaboration with Parkinson’s UK
16th Apr 20217:00 amRNSDirectors’ Subscription for new Ordinary Shares
15th Apr 20215:00 pmRNSAnnual Financial Report
15th Apr 20217:00 amRNSParticipation in Jefferies Therapeutics Summit
12th Apr 20212:26 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSHow to Convert AIM Ordinary Shares into Nasdaq ADS
1st Apr 20217:00 amRNSFinal Results
26th Mar 20213:21 pmRNSHolding(s) in Company
25th Mar 202112:08 pmRNSHolding(s) in Company
25th Mar 20218:00 amRNSHolding(s) in Company
22nd Mar 20217:00 amRNSCompletion of Merger
18th Mar 20211:25 pmRNSResult of Meeting
17th Mar 20211:00 pmRNS4D Pharma Announces Private Placement
3rd Mar 20217:00 amRNSInvestor conference participation
1st Mar 20215:49 pmRNSExercise of Options and Total Voting Rights
1st Mar 20217:02 amRNSJohn Beck Appointed as Chief Financial Officer
1st Mar 20217:00 amRNSAppoints Paul Maier to the Board as NED
26th Feb 202112:52 pmRNSHolding(s) in Company
26th Feb 20217:02 amRNSPosting of Circular
26th Feb 20217:00 amRNSU.S. SEC Declares Registration Statement Effective
16th Feb 20217:00 amRNSMicrobiome Leaders Panel Event
8th Feb 20217:45 amRNSHolding(s) in Company
8th Feb 20217:00 amRNSOncology Clinical Collaboration
4th Feb 20212:55 pmRNSHolding(s) in Company
3rd Feb 20217:00 amRNSOncology Program Update
1st Feb 20212:10 pmRNSTotal Voting Rights
27th Jan 20217:00 amRNSHolding(s) in Company
25th Jan 20216:01 pmRNSHolding(s) in Company
21st Jan 20217:00 amRNSConference participation
30th Dec 20208:32 amRNSHolding(s) in Company
29th Dec 20205:17 pmRNSHolding(s) in Company
29th Dec 20202:24 pmRNSHolding(s) in Company
22nd Dec 20202:31 pmRNSHolding(s) in Company
18th Dec 20208:53 amRNSJoins MJFF-sponsored Parkinson’s study consortium
27th Nov 20203:42 pmRNSHolding(s) in Company
26th Nov 20207:09 amRNSRegistration Statement filed with SEC
23rd Nov 20207:00 amRNSLongevity extends Business Combination deadline
12th Nov 202012:18 pmRNSHolding(s) in Company
9th Nov 20206:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.